acute and chronic cardiopathy. Heart disease, unspecified
Conditions
Interventions
Intervention 1: Intervention group 1: Deferoxamine 10 to 20 mg/kg. Frequency and route of administration is once per day continuous IV infusion over 8 hours. Intervention 2: Intervention group 2: Defe
Treatment - Drugs
Intervention group 1: Deferoxamine 10 to 20 mg/kg. Frequency and route of administration is once per day continuous IV infusion over 8 hours.
Sponsors
Vice chancellor of research, Shiaz Univeisity of Medical Sciences
Eligibility
Sex/Gender
All
Age
2 Years to 18 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: signing informed consent; male or female aged between 2 to 18 years at screening; new pediatric cancer patients who are going to receive Anthracyclin drugs as part of their chemotherapy regimen Exclusion criteria: patients below two years old; patients with previous history of treatment with any kind of chemotherapy or radiotherapy; diagnosis of congenital heart disease, preexisting heart failure and established renal disease
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cardiac Troponin-I. Timepoint: baseline, after the first dose of doxorubicin and after chemotherapy coarse. Method of measurement: hematology analysis.;NT-proBNP. Timepoint: baseline, after the first dose of doxorubicin and after chemotherapy coarse. Method of measurement: hematology analysis.;Cardiac indexes. Timepoint: baseline, 3 and 12 months intervals. Method of measurement: Conventional and tissue doppler echocardiography. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohammad Reza Bordbar
Shiraz University of Medical Sciences
Outcome results
None listed